Developing tailored medications with mRNA technology
Özlem Türeci receives the 2023 Jung Prize for Medicine for her research into the prevention and treatment of tumour diseases, infectious diseases and other serious illnesses
Hamburg, 4 May 2023. The potential of mRNA vaccines is shaping scientific discourse today in many ways. Having helped to alleviate the effects of the COVID-19 pandemic, this potential has now become widely known. However, the fundamental and translational research as well as the development of mRNA technology that enabled the fast response, development and thus rapid availability of a vaccine against COVID-19 began decades ago. As co-founder of BioNTech, Professor Özlem Türeci is a leader in this field. Her research in immunology and mRNA technology also highlights development potential beyond COVID-19 for the prevention and treatment of tumour diseases, infectious diseases and other serious illnesses. In recognition of her achievements, she receives the Jung Prize for Medicine, which is endowed with a total of 300,000 euros, from the Jung Foundation for Science and Research. Türeci can use the prize fund for her future research as she sees fit. The Jung Prize for Medicine has been awarded since 1976 and recognises the work of researchers who have made a significant contribution to the advancement of human medicine and whose work promises to continue to do so in the future. It is one of the most highly endowed medical awards in Europe.
Hier finden Sie die Pressemitteilung zum Download.
Das Bildmaterial stellen wir Ihnen gern hier zur Verfügung.